VistaGen's Nasal Spray for Social Anxiety Disorder Falls Short in Phase III Trial | BioSpace
PH94B CL030 on the App Store
VistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxiety | Seeking Alpha
New Investigational Social Anxiety Disorder Drug Differentiates Mechanism of Action
Developing Innovative Medications for the Central Nervous System - VistaGen Therapeutics, Inc
Intranasal Therapy Misses Endpoint in Social Anxiety Disorder Trial - MPR
VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)
Effect of an Acute Intranasal Aerosol Dose of PH94B on Social and Performance Anxiety in Women With Social Anxiety Disorder | American Journal of Psychiatry
PH94B CL030 on the App Store
Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Nee
PH94B – Nucleus Medical Media
VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder - BioTuesdays
Nasal spray to treat social anxiety disorder lacks abuse potential: FDA
Psych News Alert: Experimental Nasal Spray May Treat Social Anxiety Disorder, Study Indicates
VistaGen Therapeutics Inc.: PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) (Form 8-K) - MoneyController (ID 141983)
VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder
VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder - BioTuesdays
Fasedienol - Wikipedia
VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder - BioTuesdays
VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder | S&P Global Market Intelligence
Phase 3 trial of nasal spray for treatment of anxiety disorders underway
FDA says nasal spray for social anxiety disorder lacks abuse potential
VistaGen Therapeutics, Inc.
Results of clinical trials with intranasal insulin and PH94B. | Download Scientific Diagram
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 | Clinical Research Trial Listing ( Social | Social Anxiety Disorder (SAD) | Claustrophobia | Social Phobia | Phobia ) ( NCT05011396 )
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
A Novel and Abuse-Deterrent Medication for Anxiety Disorders: VistaGen PH94B
